patent
Enable an AI agent to recognise a patent, assess the evidence for its scope and current state, and identify actions that require further verification or authority.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Codex + Grok
Purpose and description
Enable an AI agent to recognise a patent, assess the evidence for its scope and current state, and identify actions that require further verification or authority.
A patent is a territorial exclusive right, granted by a government patent office after examination (or in some systems after registration), that entitles the patent holder, for a limited term, to exclude others from making, using, offering for sale, selling, or importing a claimed invention, in exchange for public disclosure of that invention in a specification whose claims define the legal scope of protection.
It can be Resolve an asserted patent identifier against authority records and distinguish it from related application or publication identifiers.; Retrieve and compare relevant claim versions, preserving the events that changed them.; Assemble a dated, territory-specific state assessment with explicit evidence gaps.; Trace recorded rights relationships and identify missing evidence of authority to maintain, license, or transfer the patent.; Prepare maintenance or review tasks from verified events and deadlines.; Frame a claim-specific technical or legal review without treating a preliminary match as an infringement or freedom-to-operate conclusion..
Distinguishing features
An asserted grant can be matched to an issuing authority and grant record; an application publication alone does not establish that the model represents a granted patent.
The protected subject matter is identified through a particular claim set, rather than inferred solely from the title, abstract, or a product description.
The record represents an individually identifiable right rather than treating related national grants or an entire patent family as one patent.
The patent is distinguished from the underlying invention: technical disclosure, ownership of a prototype, or use of an idea does not by itself identify the patent right.
An expired, revoked, or otherwise inactive patent remains identifiable as a patent, while its present action possibilities must be assessed separately.
Scope
+ Patent identity and its relationship to application, publication, and grant records
+ Claims and the documentary context needed to interpret their boundaries
+ Territorial coverage, relevant dates, and evidence of current legal state
+ Inventorship, ownership, and recorded interests affecting authority to act
+ Maintenance, challenge, and exploitation events affecting the patent
- The invention as a technical design, implementation, or scientific discovery
- Patent applications as independently managed prosecution matters
- Patent families and portfolios as aggregate assets
- Licence and assignment agreements as complete contractual instruments
- Infringement litigation as a complete legal proceeding
- Products, markets, and businesses that practise or commercialise an invention
Characteristics
- Authority-qualified patent identity
- Issuing authority, identifier, and document kind as recorded by the source Prevents applications, publications, grants, and similarly numbered records from being conflated.
- Grant verification
- Verified grant | asserted grant awaiting verification | conflicting evidence Determines whether the record can confidently be treated as an individual patent.
- Relevant claim set
- Link to a dated claim text and the event establishing its relevance Scope assessments depend on which claims and version are being considered.
- Territorial effect
- Jurisdictions or territories, each with dated supporting evidence An action assessment must address the place where the contemplated conduct occurs.
- Recorded legal state
- Source-reported status by territory and effective date; unresolved conflicts retained A historical grant record does not establish the patent's current state.
- Relevant dates and deadlines
- Calendar dates with event type, jurisdiction, source, and whether observed or calculated Supports time-sensitive review without presenting an unverified calculation as a legal deadline.
- Rights-holder relationships
- Inventor, applicant, recorded proprietor, asserted owner, licensee, or other evidenced interest Different relationships support different conclusions about control and authority.
- State evidence freshness
- Source retrieval timestamp and source-stated update or effective date Reveals when a state assessment needs refreshing before an action.
Also called
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.patent-communication
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 5 bundles · 9 layers · 16 findings · 28 questions.
Patent identity and lineage Establishes which individual patent is represented and how its documentary history connects to related records.
Patent searches expose multiple identifiers and related documents that can otherwise be mistaken for the same right.
Grant identification
Separates evidence of a grant from evidence of filing or publication.
Authority and grant record
Records the authority-qualified identity and the evidence supporting treatment as a granted patent.
- Which issuing authority, patent identifier, and document kind identify this patent? definition
- Which authoritative record establishes the grant, and what grant date does it report? provenance
Application and family links
Connects the patent to its originating application, asserted priority, and related rights without merging them.
Documented lineage
Distinguishes document versions and procedural ancestry from separate patents concerning related subject matter.
- Which application and publication records belong to this patent, and which sources establish those links? provenance
- Which priority or family relationships are recorded, and which linked records represent distinct rights rather than alternate identifiers? boundary
Claims and technical boundaries Identifies the claim text under consideration and the technical distinctions needed to examine its scope.
A patent's title or abstract cannot substitute for identifying the relevant claims and their limitations.
Claim text and version
Establishes the provenance and procedural relevance of each claim set.
Relevant claim set
Preserves the claims used for an assessment, including dependencies and evidenced changes.
- Which claim text is relevant to the territory and date being assessed, and where was it obtained? provenance
- Which claims are independent or dependent, and which documented events amended, cancelled, or otherwise affected them? definition
Claim interpretation
Connects claim language to technical evidence while preserving uncertainty about legal interpretation.
Limitations and interpretive evidence
Identifies material claim limitations and the supporting or conflicting evidence needed to interpret them.
- Which technical features or steps does each claim require, including limitations incorporated through dependency? boundary
- Which passages, drawings, prosecution records, or decisions bear on disputed terms, and which interpretations remain unsettled? provenance
- What additional technical evidence or qualified review is needed before using a claim comparison to support a proposed action? action
Territorial and temporal state Assesses where and when the patent has a recorded effect and which events may alter that assessment.
Grant, territorial effect, maintenance, and challenge outcomes must be evaluated at the relevant place and time.
Territory and status
Records jurisdiction-specific state with effective dates and source freshness.
Dated territorial effect
Separates evidenced territorial state from assumptions based on a grant or family relationship.
- For the proposed place and date of activity, what evidence establishes this patent's territorial effect? boundary
- What state does the relevant authority report, when did it take effect, and when was the record checked? measurement
- Do missing records or conflicting status reports prevent a reliable assessment for any relevant territory? provenance
Maintenance and state-changing events
Tracks obligations and proceedings that may affect duration, scope, or continued effect.
Obligations and intervening events
Records evidenced payments, deadlines, term adjustments, and proceedings without assuming their consequences.
- Which maintenance obligations or term-related dates are verified, and what evidence supports any calculated deadline? measurement
- Which lapse, restoration, surrender, challenge, or review events are recorded, and what effect has been confirmed rather than merely requested? provenance
- What next maintenance or review action is indicated, by when, and whose authority is needed to carry it out? action
Rights and action authority Connects evidenced interests in the patent to the authority and information needed for contemplated actions.
Identifying a patent or a named inventor does not establish who may control it or authorise a transaction.
Ownership and interests
Distinguishes named roles and traces evidence of ownership and other interests.
Rights chain and role separation
Records who is associated with the patent, in what capacity, and with what supporting evidence.
- Who is named as inventor, applicant, recorded proprietor, and asserted current owner, and which sources support each role? provenance
- Which transfers, co-ownership arrangements, licences, or other interests affect control, and where are the evidential gaps? boundary
Contemplated use and disposition
Frames a specific action against the patent's evidenced scope, state, and rights relationships.
Action-specific readiness
Determines what is established and what must be resolved before maintaining, licensing, transferring, asserting, or relying on the patent.
- What action is proposed, by which actor, for which territory and date, and what evidence establishes that actor's authority? action
- Which claim, status, ownership, or agreement uncertainties must be resolved before that action proceeds? action
- Which separate patents, permissions, or product-specific assessments must be considered before treating this patent as support for permission to practise an invention? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- utility patent (invention patent): protects a new, useful, and non-obvious product, process, machine, or composition of matter
- design patent / registered design: protects the ornamental appearance of an article, not its technical function
- plant patent / plant variety protection: protects asexually reproduced plant varieties (US plant patent) or distinct plant varieties under UPOV-style PVP systems
- utility model / petty patent / short-term patent: a shorter, often less-examined right for incremental technical inventions (e.g. Germany Gebrauchsmuster, China utility model)
- provisional patent application: a priority-preserving filing that is not itself examined or granted (US; analogous priority filings elsewhere)
- standard-essential patent (SEP): a patent declared essential to a technical standard, typically licensed on FRAND terms
- software / computer-implemented invention patent: claims a technical contribution implemented in software, eligibility of which varies sharply by jurisdiction
- pharmaceutical / biotech patent (including secondary patents and SPCs): composition, process, formulation, or use claims, often extended by supplementary protection certificates
- Which of these kinds and varieties hold for the sense of patent this model covers, and on what evidence? provenance
Identifiers and schemes
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Wikidata - Q253623 (patent as legal instrument); also Q101333 / instance-of patent documents - The concept 'patent' is Q253623; individual granted patents and applications are usually modelled as documents with identifiers below.
- ST.16 type / kind codes (WIPO) - letter-plus-number kind code after the publication number, e.g. A1 (first publication of application), B1 (granted patent), U (utility model) - codes are office-specific - Kind codes distinguish application, grant, correction and utility-model publications for the same number.
- ST.3 office code + national/regional number (WIPO) - CC + serial, e.g. US11234567B2, EP3123456A1, WO2024/123456A1, CN112345678A - Country/office code (ST.3) plus document number plus kind code is the usual human citation form.
- application number - office-assigned filing number, often with year, e.g. US 17/123,456; PCT/US2024/012345; EP 24123456.7 - Identifies the pending file, not the published or granted document.
- publication number - number assigned when the specification is published, commonly 18 months from priority - Distinct from the application number and, in many offices, from the grant number.
- DOCDB / INPADOC family ID (EPO) - integer family identifier grouping documents that share a priority - Used to treat territorial counterparts as one invention family.
- CPC / IPC classification - IPC: section-class-subclass-group, e.g. A61K 31/00; CPC adds finer subdivisions - Subject-matter classification of the invention, not an identity of the legal right.
- priority number (Paris Convention) - first-filing office + number + date, claimed within 12 months - Links later filings in other countries to the same invention's priority date.
- Which of these identifiers and schemes hold for the sense of patent this model covers, and on what evidence? provenance
Standards and regulation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- WTO TRIPS Agreement (1994, as amended), Arts. 27-34 - World Trade Organization: minimum patentability, rights, term (20 years from filing), and compulsory-licence conditions for WTO members
- Paris Convention for the Protection of Industrial Property (1883, as revised) - WIPO: national treatment and 12-month priority right
- Patent Cooperation Treaty (PCT, 1970) - WIPO: international application, international search and preliminary examination, then national/regional phase
- WIPO ST.3, ST.9, ST.13, ST.14, ST.16, ST.26, ST.36/ST.96 - WIPO: office codes, bibliographic data, application numbering, kind codes, sequence listings, XML patent document formats
- European Patent Convention (EPC, 1973 as revised) - European Patent Organisation / EPO: unitary grant procedure for contracting states; Art. 52-57 patentability; opposition; Unitary Patent and Unified Patent Court overlay for participating EU states
- 35 U.S.C. (Patent Act) and USPTO Manual of Patent Examining Procedure (MPEP) - United States: utility, design and plant patents, AIA first-inventor-to-file, term, PTA/PTE
- EU Regulation (EC) No 469/2009 (medicinal products) and (EC) No 1610/96 (plant protection products) - European Union: supplementary protection certificates extending patent-like protection after grant
- National patent acts and office guidelines (e.g. China Patent Law and CNIPA guidelines; Japan Patent Act and JPO; India Patents Act 1970 as amended, including s.3(d) for pharmaceuticals) - each territorial office
- Which of these standards and regulation hold for the sense of patent this model covers, and on what evidence? provenance
Real-world use
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- An inventor or company files a specification and claims at a national or regional office (or via PCT), paying filing, search, examination, grant and renewal fees; the application is typically published at 18 months and may grant years later after examination.
- The granted claims are used to exclude competitors, to license (exclusive, non-exclusive, FRAND for SEPs), to collateralise finance, to list in Orange Book / patent registers for medicines, and to support customs recordation against infringing imports.
- Freedom-to-operate (FTO) searches treat other parties' patents as blocking rights that must be designed around, licensed, or invalidated before product launch.
- Litigation and opposition (EPO opposition within 9 months of grant; USPTO IPR/PGR; national revocation) are the usual ways the right is tested; most patents never go to court.
- In standards bodies (ETSI, ITU, IEEE) companies declare SEPs and commit to FRAND licensing; in pharma, patents gate generic entry until expiry or SPC/PTE end, then data/market exclusivity may still block.
- Which of these real-world use hold for the sense of patent this model covers, and on what evidence? provenance
Typical measurements
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- maximum term of a utility/invention patent - 20 from filing date (TRIPS minimum; extensions via SPC/PTE/PTA can add years, commonly up to about 5 extra in medicines) - year
- Paris / PCT priority window - 12 from first filing - month
- pre-grant publication lag - 18 from earliest priority (or earlier on request); some offices defer or withhold until grant - month
- design-patent term (US, post-13 May 2015 filings) - 15 from grant - year
- utility-model term (typical) - 6 to 10 from filing, office-dependent - year
- maintenance / renewal fee cadence - annual in most EPO/national systems; USPTO at 3.5, 7.5 and 11.5 years after grant - year
- claim count in a typical utility filing - about 10 to 30 independent-plus-dependent claims before excess-claim fees bite; complex families can run to hundreds - count
- grant lag (application to grant) - roughly 2 to 5 for many major offices on a straightforward case; longer with continuations, divisionals, or oppositions - year
- Which of these typical measurements hold for the sense of patent this model covers, and on what evidence? provenance
Failure modes and hazards
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Invalidity after grant: claims anticipated or obvious over prior art, insufficient disclosure, added matter, or ineligible subject matter (abstract ideas, laws of nature, medical methods in some offices).
- Lapse for non-payment of renewal/maintenance fees, or failure to enter national phase of a PCT in time.
- Over-broad or poorly enabled claims that do not survive opposition or litigation, leaving the holder with a paper right.
- Infringement of others' patents (including SEPs) despite holding one's own patent - a patent is a right to exclude, not a right to practise.
- Evergreening / secondary pharmaceutical patents and thickets that delay generic or biosimilar entry, raising medicine prices and access concerns.
- Hold-up and royalty stacking around SEPs when FRAND commitments are disputed.
- Territorial holes: no protection where not filed; parallel imports and compulsory licences (TRIPS Art. 31, Doha Declaration on public health) can limit enforcement.
- Fraud on the office or inequitable conduct (US) can render the patent unenforceable; wilful infringement can multiply damages.
- Which of these failure modes and hazards hold for the sense of patent this model covers, and on what evidence? provenance
Regional variation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- United States: three statutory types (utility, design, plant); first-inventor-to-file since AIA 2013; grace period for inventor-originated disclosures; design term 15 years from grant; no utility models.
- Europe (EPC / UPC): single EPO grant then national or unitary effect; no US-style grace period in general; medical methods excluded (Art. 53(c) EPC); software as such excluded (Art. 52) unless a technical effect is shown; Germany and others also offer utility models.
- China: invention patents plus a large utility-model system and design patents; CNIPA examination practice and dual-filing (invention + utility model) are distinctive.
- Japan and Republic of Korea: strong examination, utility models (Japan's is now largely registration-based), and relatively high grant quality metrics.
- India: no patents on plants, animals, or methods of agriculture/medicine as such; s.3(d) restricts new forms of known substances without enhanced efficacy; compulsory licensing used in public-health cases.
- Latin America and LDC TRIPS flexibilities: some offices historically delayed pharma product patents; least-developed WTO members have transition periods; Andean and other regional regimes differ on second-use claims.
- Naming: 'patent' vs 'invention patent' (CN), 'brevet' (FR), 'Patent / Gebrauchsmuster' (DE), 'utility model' / 'petty patent' / 'innovation patent' (AU innovation patent abolished 2021).
- Which of these regional variation hold for the sense of patent this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- copyright - Copyright arises automatically in original expressive works and does not protect abstract technical ideas or functional methods; a patent requires filing, examination (usually), and claims a novel technical invention for a short term.
- trade secret / undisclosed information - A trade secret lasts while secrecy is maintained and never requires disclosure; a patent requires enabling public disclosure and expires on a fixed term. Reverse engineering a secret is generally allowed; practising a valid patent claim is not.
- utility model / petty patent - Same industrial-property family but typically shorter term, lower inventiveness threshold, and little or no substantive examination; not every office offers it, and TRIPS does not require it.
- registered design / design patent / industrial design - Protects ornamental appearance of a product, not technical function; test is visual overall impression / novelty of appearance, not inventive step of a technical teaching. (US confusingly calls this a 'design patent'.)
- plant variety right (UPOV PVP) - PVP protects a distinct, uniform, stable variety as such, with breeder's-exemption and farm-saved-seed rules; a plant patent (US) or biotech patent claims a specific asexually reproduced plant or a genetic/technical invention, not the UPOV variety denomination system.
- supplementary protection certificate (SPC) / patent term extension (PTE) - Not a new patent: a sui generis extension of protection for a patented authorised medicine or plant-protection product to compensate regulatory delay; it depends on an underlying basic patent and a marketing authorisation.
- defensive publication / prior-art disclosure - A publication dedicated to the public to block others from patenting; it creates no exclusive right and is the opposite legal tool from filing for a patent.
- trademark - A trademark identifies commercial origin of goods/services and can last indefinitely with use and renewal; it does not monopolise a technical solution. Confusion arises when product names and patented technologies are marketed together.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of patent this model covers, and on what evidence? provenance
Sources
- Patents - WIPO's definition of a patent as an exclusive right granted for an invention, the public-disclosure bargain, territoriality, and the typical 20-year term from filing.
- Frequently Asked Questions: Patents - Practical distinctions among utility, design and plant patents; utility models; patentability criteria (novelty, inventive step, industrial applicability); first-to-file; PCT international applications; and that a patent is not a right to use but a right to exclude.
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Articles 27-34 - The WTO floor: patents available for products and processes in all fields of technology; exclusions (ordre public, diagnostic/therapeutic/surgical methods, plants and animals); 20-year minimum term from filing; exclusive rights to prevent making, using, offering for sale, selling, or importing; compulsory-licence conditions in Article 31.
- Patent basics / Patents - US practice: utility, design and plant patents; 20-year term from non-provisional filing for utility/plant (subject to PTA/PTE); 15-year term from grant for design patents filed on or after 13 May 2015; role of the USPTO as examining office.
What the second pass must settle
- Does the registry's patent entry include design and plant patents or analogous protection types, and which require distinct questions or neighbouring models?
- How should regional grants, national validations, and unitary effects be represented while preserving the registry's authoritative granularity?
- Which authority records and update intervals are sufficient to support each jurisdiction's status and maintenance assessments?
- Which jurisdiction-specific rules and evidence are required to verify term calculations, restoration possibilities, and the effects of pending challenges?
- What evidence and qualified review are required before recorded ownership or a claim comparison can support a consequential action?